Delayed Immunomodulation Improves Immune Dysfunction in a Murine Model of PICS.

Area of Science:

• Immunology
• Critical Care Medicine
• Sepsis Research

Background:

• Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) is a critical illness following sepsis.
• Current treatments for PICS lack interventions to reverse its immune dysfunction.
• Understanding PICS immune responses is crucial for developing new therapies.

Purpose of the Study:

• To characterize immune responses in a murine PICS model.
• To evaluate immunomodulatory agents (G-CSF, GM-CSF, anti-PD-L1) for reversing PICS-induced immune dysfunction.
• To assess treatment efficacy after the acute sepsis phase.

Main Methods:

• Utilized a cecal ligation and puncture (CLP) mouse model to induce PICS.
• Administered G-CSF, GM-CSF, and anti-PD-L1 antibody post-CLP (after day four).
• Assessed immune cell counts, function, surface marker expression (MHC-II, CD11b), and cytokine production (INFγ).
• Evaluated bacterial clearance and survival following secondary Pseudomonas aeruginosa infection.

Main Results:

• Anti-PD-L1 therapy demonstrated superior efficacy over G-CSF and GM-CSF in reversing immunosuppression.
• Improvements were observed in immune cell numbers, function, MHC-II/CD11b expression, and T cell INFγ production.
• Anti-PD-L1 treatment did not enhance bacterial clearance of Pseudomonas aeruginosa.
• Despite reduced bacterial clearance, anti-PD-L1 therapy improved survival in CLP mice (100%) compared to controls (60%).

Conclusions:

• Anti-PD-L1 therapy shows potential in mitigating immune dysfunction associated with PICS.
• This therapy may improve host defense against secondary infections post-sepsis.
• Further research is warranted to optimize anti-PD-L1 therapy for PICS management.